Overview

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study is phase II, open label, clinical trial of durvalumab to identify immune dynamics in operable non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Yonsei University
Treatments:
Durvalumab